Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.
about
New criteria for response assessment: role of minimal residual disease in multiple myelomaRecovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myelomaDiagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based RegimensSuppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.Active multiple myeloma suppresses and typically eliminates coexisting MGUS.Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.
P2860
Q27027512-1C5658F6-B57D-46E5-A595-45FA0356F089Q33816012-D59F0DAF-98A7-4117-A3E9-DEB0D8371F20Q34557651-3278D148-2100-4FFC-8B07-409086DC9F69Q36735810-4D56662F-2F77-4716-8437-6885B12118C0Q36799760-5260A1EA-D587-4418-B3F5-CD01DD22723EQ38722312-03D9B3EA-490B-4FE1-81B0-31940683761EQ40114748-7153960C-BE26-4C4A-BC03-E17C77A4D0ACQ40742235-5F5AFBE3-80A4-4D00-8019-98BAFAD87E35Q40831660-19A1738F-AF6D-46A2-A68B-C8DEA41C5788Q42250752-A8CAE0D0-6C14-4AE9-B21A-390E17705BDBQ47102955-6B71200C-035B-483E-9292-D41214EBC89EQ47679443-AABF6E77-4F9E-4DE6-8506-B36C000EA3FBQ48156924-AA7F77A8-F21C-4D21-A37E-2414C0C4EB0AQ49913606-A1C92BFF-2293-4863-BA35-649B229F21A9Q50224356-14411C28-8BC1-4E48-ABEA-D9518C488C3F
P2860
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Preserved levels of uninvolved ...... symptomatic multiple myeloma.
@en
Preserved levels of uninvolved ...... symptomatic multiple myeloma.
@nl
type
label
Preserved levels of uninvolved ...... symptomatic multiple myeloma.
@en
Preserved levels of uninvolved ...... symptomatic multiple myeloma.
@nl
prefLabel
Preserved levels of uninvolved ...... symptomatic multiple myeloma.
@en
Preserved levels of uninvolved ...... symptomatic multiple myeloma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Preserved levels of uninvolved ...... h symptomatic multiple myeloma
@en
P2093
A Christophoridou
C Megalakaki
E Katodritou
E Michalis
E Stefanoudaki
P2860
P2888
P304
P356
10.1038/LEU.2014.110
P577
2014-03-18T00:00:00Z